title: Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma.
abstract: Preclinical studies have suggested that sunitinib accelerates metastases in animals, ascribing this to inhibition of the vascular endothelial growth factor receptor or the tumor's adaptation. To address whether sunitinib accelerates tumors in humans, we analyzed data from the pivotal randomized phase III trial comparing sunitinib and interferon alfa in patients with metastatic renal cell carcinoma. The evidence clearly shows that sunitinib was not harmful, did not accelerate tumor growth, and did not shorten survival. Specifically, neither longer sunitinib treatment nor a greater effect of sunitinib on tumors reduced survival. Sunitinib did reduce the tumor's growth rate while administered, thereby improving survival, without appearing to alter tumor biology after discontinuation. Concerns arising from animal models do not apply to patients receiving sunitinib and likely will not apply to similar agents.
authors: National Science Foundation, Arlington, VA 22030, USA. kblagoev@nsf.gov
authors: Krastan B
authors: KB
authors: Blagoev
authors: Julia
authors: J
authors: Wilkerson
authors: Wilfred D
authors: WD
authors: Stein
authors: Robert J
authors: RJ
authors: Motzer
authors: Susan E
authors: SE
authors: Bates
authors: A Tito
authors: AT
authors: Fojo
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D049109:Cell Proliferation; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D016898:Interferon-alpha; D011758:Pyrroles; D000077210:Sunitinib
references: Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):789-91
references: 19164810
references: Cancer Cell. 2009 Mar 3;15(3):220-31
references: 19249680
references: N Engl J Med. 1971 Nov 18;285(21):1182-6
references: 4938153
references: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references: 10655437
references: Clin Cancer Res. 2012 Apr 15;18(8):2374-81
references: 22344231
references: Recent Results Cancer Res. 2010;184:71-82
references: 20072832
references: J Clin Oncol. 2009 Aug 1;27(22):3584-90
references: 19487381
references: Cancer Cell. 2009 Mar 3;15(3):232-9
references: 19249681
references: Cell. 2011 Sep 16;146(6):873-87
references: 21925313
references: Cell. 2011 Mar 4;144(5):646-74
references: 21376230
references: Oncologist. 2008 Oct;13(10):1055-62
references: 18827177
references: J Exp Med. 1971 Feb 1;133(2):275-88
references: 4332371
references: Clin Cancer Res. 2006 Sep 1;12(17):5018-22
references: 16951216
references: N Engl J Med. 2007 Jan 11;356(2):115-24
references: 17215529
references: BioDrugs. 2009;23(6):377-89
references: 19894779